What is it? Why is it important?

Risk evaluation includes to assess the significance of identified study risks, such as:

  • The likelihood or frequency that a risk occurs
  • The detectability or ability to identify a risk in a timely manner
  • The expected impact of a risk on the integrity of study defined Critical to Quality (CtoQ) factors (e.g. low, medium, high impact)
  • The rating of the risk based on how difficult, how likely, or how easy can the risk be detected

 

Risk prioritisation includes to decide which risks matter most, such as:

  • To set risk priorities based on risk evaluation
  • How will risk-priority affect the implementation of risk control-measures and the investment of resources, such as:
    • Adaptations in monitoring intensity and frequency, with higher priority risks receiving more robust oversight
    • Required adaptations in trial conduct to minimize participant burden while guaranteeing data quality

 

Both the SP-INV (i.e on study level) and Site-INV(s) (i.e. on site level) are responsible to evaluate and prioritize risks threatening CtoQ factors.

What do I need to do?

As a SP-INV or Site-INV evaluate and prioritise identified study risks, consider:

  • The frequency and detectability of potential errors
  • The potential impact on the study`s CtoQ factors (e.g. participant right and safety, data quality)
  • The evolving risk profile throughout the trial lifecycle, and plan procedures for the periodic reassessment of study risks, including the efficacy and applicability of implemented risk control-measures

 

Apply these principles by using:

  • A Quality by Design (QbyD) approach, with the aim to manage risks before they occur, thereby providing credible and useful study results
  • A Risk Evaluation Matrix (REM) or other risk assessment tool to:
    • Regularly check risk impact on the study`s CtoQ factors
    • Set clear priorities for actions to reduce risks and monitor trial activities
    • Apply quality control measures proportionate to risk level
    • Work as a multidisciplinary team to continuously review risks and respond in a timely way

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guidelines

  • 3.10 Quality management
  • 3.10.1.2 Risk evaluation
  • 3.10.1.6 Risk review

ICH E8(R1) – see in particular

  • 3.1 Quality by Design of clinical studies
  • 3.2 Critical to Quality Factors

ISO 31000 (access liable to costs) – see in particular section

  • Risk management: Principles and guidelines

Documents

Abbreviations
  • CtoQ - critical-to-quality factors
  • CTU – Clinical Trials Unit
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • ICH - International Council for Harmonisation
  • ISO – International Organization for Standardization
  • QbyD - Quality by Design
  • REM – Risk Evaluation Matrix
  • Site-INV – Site Investigator
  • SP-INV – Sponsor-Investigator
Basic ↦ Quality and Risk ↦ Risk-Based Approach to Quality ↦ Risk Evaluation and Prioritisation
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Basic ↦ Quality and Risk ↦ Risk-Based Approach to Quality ↦ Risk Evaluation and Prioritisation